Acadia Pharmaceuticals Unveils Key Neurological Data at AAN 2026 — Acadia Pharmaceuticals Inc.

Event summary

Acadia Pharmaceuticals will present six data sets at the 2026 AAN Annual Meeting in Chicago, April 18–22.
Key focus areas include Rett syndrome (DAYBUE), Parkinson’s disease psychosis (NUPLAZID), and essential tremor (ACP-711).
Real-world data from the LOTUS study on DAYBUE’s benefits and tolerability in adults with Rett syndrome will be highlighted.
Exploratory analyses of NUPLAZID’s treatment response trajectories and baseline sleep disturbances in PDP patients are included.

The big picture

Acadia Pharmaceuticals is positioning itself as a leader in neurological and rare disease treatments, with a focus on expanding the clinical evidence base for its existing products while advancing new candidates. The data presentations at AAN 2026 underscore the company’s commitment to addressing unmet needs in conditions like Rett syndrome, Parkinson’s disease psychosis, and essential tremor. This strategic move aligns with broader industry trends toward personalized medicine and real-world evidence in drug development.

What we're watching

Clinical Validation: Whether the real-world data from the LOTUS study will reinforce DAYBUE’s efficacy and tolerability in Rett syndrome.
Pipeline Progress: The pace at which ACP-711 advances through development for essential tremor, given the translational research being presented.
Market Differentiation: How Acadia’s exploratory analyses of NUPLAZID could refine treatment approaches for Parkinson’s disease psychosis.